Novan Announces Strategic Priorities and Outlines Key Milestones
September 09, 2021 07:00 ET
|
Novan, Inc.
– Company planning for three potential New Drug Application (NDA) filings in three years with the first submission expected in Q3 2022 for lead program SB206 in molluscum contagiosum – – Late-stage...
Novan Engages Syneos Health as Commercial Solutions Provider for SB206
September 08, 2021 09:00 ET
|
Novan, Inc.
– Company targeting New Drug Application (NDA) for SB206 in Q3 2022, following recent clinically and statistically significant topline efficacy results from a pivotal Phase 3 B-SIMPLE4 trial in...
Novan to Present at H.C. Wainwright 23rd Annual Global Investment Conference
September 07, 2021 09:00 ET
|
Novan, Inc.
DURHAM, N.C., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that Paula Brown Stafford, President and Chief Executive Officer of Novan,...
Novan to Host Corporate Update Conference Call and Webcast on September 9, 2021
September 02, 2021 09:05 ET
|
Novan, Inc.
– Conference call with live audio webcast to be held on Thursday, September 9th at 8:30 a.m. ET – DURHAM, N.C., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq:...
Novan Appoints Tomoko Maeda-Chubachi, MD, PhD, MBA as Chief Medical Officer
August 24, 2021 09:00 ET
|
Novan, Inc.
– Dr. Maeda-Chubachi, who served as Novan’s Senior Vice President, Medical has played a key role in the design and execution of the Company’s development programs – – Dr. Maeda-Chubachi was...
Novan Reports Second Quarter 2021 Financial Results and Provides Corporate Update
August 12, 2021 07:05 ET
|
Novan, Inc.
– Positive data across all three of the Company’s priority pipeline development programs, announced in Q2 2021, further validating the potential of its novel, proprietary NITRICIL™ technology – –...
Novan to Report Second Quarter 2021 Financial Results on August 12, 2021
August 05, 2021 08:05 ET
|
Novan, Inc.
DURHAM, N.C., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its second quarter 2021 financial results on Thursday,...
Novan Announces Last Patient Visit at Week 24 in B-SIMPLE4 Pivotal Phase 3 Trial of SB206 in Patients with Molluscum Contagiosum
July 28, 2021 08:05 ET
|
Novan, Inc.
– Company previously reported positive topline efficacy and favorable safety data at Week 12 from B-SIMPLE4 in June 2021, with primary endpoint achieving statistical significance with p-value less...
Novan Announces Inclusion in Russell Microcap® Index
June 24, 2021 08:05 ET
|
Novan, Inc.
DURHAM, N.C., June 24, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that as part of the annual reconstitution of the Russell stock indexes, Novan...
Novan Announces Closing of $40 Million Public Offering of Common Stock
June 21, 2021 16:01 ET
|
Novan, Inc.
DURHAM, N.C., June 21, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (the “Company" or "Novan") (NASDAQ:NOVN) today announced the closing of the Company's previously announced underwritten public offering...